Law Firm Challenges Centessa $38 Cash Plus Up to $9 CVR Sale to Lilly
Centessa Pharmaceuticals shareholders will receive $38 in cash per share plus one non-transferrable contingent value right for up to an additional $9 based on milestone achievements in its sale to Eli Lilly. Halper Sadeh LLC is investigating potential fiduciary duty breaches and deal terms that may restrict competing offers.
1. Deal Terms for Shareholders
Centessa Pharmaceuticals agreed to be acquired by Eli Lilly for $38.00 in cash per ADR plus one non-transferrable contingent value right entitling holders to up to $9.00 in additional payments upon achievement of specified development and regulatory milestones.
2. Legal Investigation and Implications
Investor rights law firm Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the transaction, including clauses that could limit superior competing offers and seek increased consideration or additional disclosures for shareholders.